» Articles » PMID: 31654635

Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter Pylori Infection: A Large Cohort Study

Overview
Specialty Gastroenterology
Date 2019 Oct 27
PMID 31654635
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Nearly all studies of gastric adenocarcinoma in the United States have relied on national cancer databases, which do not include data on Helicobacter pylori infection, the most well-known risk factor for gastric cancer. We collected data from a large cohort of patients in the United States to calculate the incidence of and risk factors for nonproximal gastric adenocarcinomas after detection of H pylori. Secondary aims included identifying how treatment and eradication affect cancer risk.

Methods: We performed a retrospective cohort study, collecting data from the Veterans Health Administration on 371,813 patients (median age 62 years; 92.3% male) who received a diagnosis of H pylori infection from January 1, 1994, through December 31, 2018. The primary outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylori infection. We performed a time to event with competing risk analysis (with death before cancer as a competing risk).

Results: The cumulative incidence of cancer at 5, 10, and 20 years after detection of H pylori infection was 0.37%, 0.5%, and 0.65%, respectively. Factors associated with cancer included older age at time of detection of H pylori infection (subhazard ratio [SHR], 1.13; 95% confidence interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), Asian race (SHR, 2.52; 95% CI, 1.64-3.89) (P < .001 for race), Hispanic or Latino ethnicity (SHR, 1.59; 95% CI, 1.34-1.87; P < .001), and history of smoking (SHR, 1.38; 95% CI, 1.25-1.52; P < .001). Women had decreased risk of gastric adenocarcinoma compared with men (SHR, 0.52; 95% CI, 0.40-0.68; P < .001); patients whose H pylori infection was detected based on serum antibody positivity also had a reduced risk of cancer (SHR 0.74; 95% CI, 0.54-1.04; P = .04). Patients who received treatment for their H pylori infection still had an increased risk of gastric cancer (SHR, 1.16; 95% CI, 0.74-1.83; P = .51) but confirmed H pylori eradication after treatment reduced risk of gastric cancer (SHR, 0.24; 95% CI, 0.15-0.41; P < .001).

Conclusions: In a study of 371,813 veterans with a diagnosis of H pylori infection, we found significantly higher risks of gastric cancer in racial and ethnic minorities and smokers. Treatment of H pylori infection decreased risk only if eradication was successful. Studies are needed on the effects of screening high-risk persons and to identify quality measures for diagnosis, resistance patterns, and treatment efficacy.

Citing Articles

Analysis of biopsies of gastric cancer, intestinal and diffuse, and non-atrophic gastritis: an overview of loss of heterozygosity in Mexican patients.

Larios-Serrato V, Valdez-Salazar H, Torres J, Camorlinga M, Pina-Sanchez P, Minauro F PeerJ. 2025; 13:e18928.

PMID: 40028213 PMC: 11869887. DOI: 10.7717/peerj.18928.


Superoxide dismutase promotes gastric tumorigenesis mediated by and enhances resistance to 5-fluorouracil in gastric cancer.

Fu H, Zhang Y, Duan Y, Zhang X, Yao J, Yang D iScience. 2025; 28(2):111553.

PMID: 39898027 PMC: 11787496. DOI: 10.1016/j.isci.2024.111553.


An oral microbiota-based deep neural network model for risk stratification and prognosis prediction in gastric cancer.

Gao X, Zhang C, Huang K, Zhao X, Liu Y, Wang Z J Oral Microbiol. 2025; 17(1):2451921.

PMID: 39840394 PMC: 11749243. DOI: 10.1080/20002297.2025.2451921.


Occurrence of in drinking water sources and antimicrobial resistance profile in the central region of Peru.

Custodio M, Montalvo-Otivo R, Crispin-Ayala J, Bendezu-Meza J, Herrera-Quintana P, De la Cruz H Heliyon. 2025; 11(1):e41533.

PMID: 39834420 PMC: 11743314. DOI: 10.1016/j.heliyon.2024.e41533.


New pathogen for gastric cancer: Streptococcus anginosus.

Zeng R, Sung J, Yu J Clin Transl Med. 2024; 14(12):e70104.

PMID: 39605236 PMC: 11602752. DOI: 10.1002/ctm2.70104.


References
1.
Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

2.
Kim J, Cheung D . Must-Have Knowledge about the Helicobacter pylori-Negative Gastric Cancer. Gut Liver. 2016; 10(2):157-9. PMC: 4780443. DOI: 10.5009/gnl16002. View

3.
Correa P, Piazuelo M . Helicobacter pylori Infection and Gastric Adenocarcinoma. US Gastroenterol Hepatol Rev. 2011; 7(1):59-64. PMC: 3158605. View

4.
Wu C, Kuo K, Wu M, Chen Y, Wang C, Lin J . Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009; 137(5):1641-8.e1-2. DOI: 10.1053/j.gastro.2009.07.060. View

5.
Siegel R, Naishadham D, Jemal A . Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012; 62(5):283-98. DOI: 10.3322/caac.21153. View